Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases

Journal of Clinical Pathology

Volumn 64, Issue 1, 2011, Pages 75-82

  Tognon, Raquel ^a,b   Gasparotto, Elainy Patrícia Lino ^a,b   Leroy, Janine Marie Gisele ^a   Oliveira, Gislane Lelis Vilela ^a,b   Neves, Renata Peres ^a,b   Carrara, Rita De Cássia Viu ^a   Kashima, Simone ^a   Covas, Dimas Tadeu ^a   Santana, Mary ^c   Souto, Elizabeth Xisto ^c   Zanichelli, Maria Aparecida ^c,e   Velano, Carlos Eduardo Engel ^a   Simões, Belinda Pinto ^a   Alberto, Fernando Lopes ^d   Miyashiro, Kozue ^d   De Souza, Ana Maria ^a,b   Amarante Mendes, Gustavo Pessini ^a   De Castro, Fabíola Attié ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INCT IF ^*  (Brazil)

^c Brigadeiro Hospital of São Paulo   (Brazil)

^d Fleury   (Brazil)

^e Institute for Cancer Treatment in Children ITACI   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; COMPLEMENTARY DNA; DEATH RECEPTOR; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; JANUS KINASE 2; RNA;

ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL CULTURE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; EVALUATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; LEUKOCYTE; MALE; MONONUCLEAR CELL; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; APOPTOSIS; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; HUMANS; JANUS KINASE 2; LEUKOCYTES; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION; RECEPTORS, DEATH DOMAIN; RNA, MESSENGER; YOUNG ADULT;

EID: 78650846476     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.080895     Document Type: Article

References (62)

1. Delhommeau F, Pisani D, James C, et al. Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci 2006;63:2939-53.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8. (Pubitemid 40663494)
3. Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004;41(2 Suppl 3):1-5.
4. Teferri A, Vardimann JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
5. Reilly JT. Idiopathic myelofibrosis: pathogenesis to treatment. Hematol Oncol 2006;24:56-63.
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
7. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
8. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
9. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-92.
10. Speletas M, Katodritou E, Daiou C, et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res 2007;31:1053-62.
11. Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-83.
12. Jones A, Kreil S, Zol K, et al. Widespread occurrence of JAK2- V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-68.
13. Ugo V, Marzac C, Teyssandier I, et al. Multiple signalling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004;32:179-87. (Pubitemid 38177643)
14. Komura E, Chagraoui H, Mansat de Mas V, et al. Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. Exp Hematol 2003;31:622-30.
15. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110:4030-6.
16. Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006;108:1865-7.
17. Larsen TS, Pallisgaard N, Møller MB, et al. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematol 2007;79:508-15.
18. Campbell PJ, Griesshammer M, Dohner K, et al. The V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006;107:2098-100.
19. Sirhan S, Lasho TL, Hanson CA, et al. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008;83:363-5.
20. Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003;102: 1869-71.
21. Mesa RA, Tefferi A, Lasho TS, et al. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia 2006;20:1800-8. (Pubitemid 44574991)
22. Wickremasinghe RG, Hoffbrand AV. Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and haematological malignancies. Blood 1999;93:3587-600.
23. Schimmer AD, Hedley DW, Penn LZ, et al. Receptor and mitochondrial- mediated apoptosis in acute leukemia: a translational view. Blood 2001;98:3541-53.
24. Debatin KM, Stahnke K, Fulda S. Apoptosis in haematological disorders. Semin Cancer Biol 2003;13:149-58.
25. Hara K, Abe Y, Hirase N, et al. Apoptosis resistance of mature neutrophils in a case of chronic neutrophilic leukaemia. Eur J Haematol 2001;66:70-1.
26. Economopoulou C, Pappa V, Kontsioti F, et al. Analysis of apoptosis regulatory genes expression in the bone marrow (BM) of adult de novo myelodysplastic syndromes (MDS). Leuk Res 2008;32:61-9.
27. Castro FA, Jacysyn JF, Ulbrich AG, et al. Overexpression of the anti-apoptotic genes mcl-1, bcl-w, bcl-xL and a1 is correlated with to Chronic Myelogenous Leukemia progression and resistance to Gleevec [ASH Annual Meeting Abstract]. Blood 2005;106:P2880.
28. Zeuner A, Pedini F, Signore M, et al. Increased death receptor resistance and FLIP short expression in polycythemia vera erythroid precursor cells. Blood 2006;107:3495-502.
29. Ciurea SO, Merchant D, Mahmud N. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 2007;110:986-93.
30. Laubach JP, Fu P, Jiang X, et al. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. Exp Hematol 2009;37:1411-22.
31. Deligezer U, Dalay N. Expression of the TRAIL Receptors in Blood Mononuclear Cells in leukemia. Pathol Oncol Res 2007;13:290-4.
32. Jin Z, El-Deiry W. Overview of cell death signalling pathways. Cancer Biol Ther 2005;4:139-63.
33. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-95.
34. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
35. Ishii T, Bruno E, Hoffman R, et al. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006;108:3128-34.
36. Delhommeau F, Dupont S, Tonetti C, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007;109:71-7.
37. Pardanani A, Lasho TL, Finke C, et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 2007;25:2358-62.
38. Bogani C, Guglielmelli P, Antonioli E, et al. B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica 2007;92:258-9.
39. Contini P, Zocchi MR, Pierri I, et al. In vivo apoptosis of CD8(+) lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand. Leukemia 2007;21:253-60.
40. Bárcena A, Park SW, Banapour B, et al. Expression of Fas/CD95 and Bcl-2 by primitive haematopoietic progenitors freshly isolated from human fetal liver. Blood 1996;88:2013-25. (Pubitemid 26307903)
41. De Maria R, Testa U, Luchetti L, et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 1999;93:796-803.
42. Alenzi FQ, Marley SB, Lewis JL, et al. A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics. Exp Hematol 2002;30:1428-35.
43. Pearl-Yafe M, Yolcu ES, Stein J, et al. Expression of Fas and Fas-ligand in donor haematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. Exp Hematol 2007;35:1601-12.
44. Rothstein TL, Zhong X, Schram BR, et al. Receptor-specific regulation of B-cell susceptibility to Fas-mediated apoptosis and a novel Fas apoptosis inhibitory molecule. Immunol Rev 2000;176:116-33.
45. Scheneider TJ, Fischer GM, Donohoe TJ, et al. A novel gene coding for a Fas apoptosis Inhibitory Molecule (FAIM) isolated from Inducible Fas-resistant B lymphocytes. J Exp Med 1999;189:949-56.
46. Sole C, Dolcet X, Segura MF, et al. The death receptor antagonist FAIM promotes neuritis outgrowth by a mechanism that depends on ERK and NF-kappa B signalling. J Cell Biol 2004;167:479-92.
47. Segura MF, Sole C, Pascual M, et al. The long form of Fas apoptotic inhibitory molecule is expressed specifically in neurons and protects them against death receptor-triggered apoptosis. J Neurosci 2007;27:11228-41.
48. Tenedini E, Fagioli ME, Vianelli N, et al. Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. Blood 2004;104:3126-35.
49. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
50. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
51. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
52. Sanlioglu AD, Korcum AF, Pestereli E, et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:716-23. (Pubitemid 47418395)
53. Cooper WA, Kohonen-Corish MR, Zhuang L, et al. Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions. Cancer 2008;113:135-42.
54. Wang X, Chen W, Zeng W, et al. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 2008;7:1156-63.
55. Han J, Hou W, Goldstein LA. Involvement of protective autophagy in TRAIL-resistance of apoptosis defective tumor cells. J Biol Chem 2008;283:19665-77.
56. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signalling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003;14:337-48.
57. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006;107:3676-82.
58. Wang W, Prince CZ, Mou Y, et al. Notch3 signaling in vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK activation: resistance to Fas ligand-induced apoptosis. J Biol Chem 2002;277:21723-9.
59. Skurk C, Maatz H, Kim HS, et al. The Akt-regulated forkhead transcription factor FOXO3a Controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem 2004;279:1513-25.
60. Starck L, Scholz C, Dorken B, et al. Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol 2005;35:1257-66.
61. Wang MJ, Liu S, Liu Y, et al. Actinomycin D enhances TRAIL-induced caspase-dependent and independent apoptosis in SH-SY5Y neuroblastoma cells. Neurosci Res 2007;59:40-6.
62. Huo J, Xu S, Guo K, et al. Genetic deletion of faim reveals its role in modulating c-FLIP expression during CD95-mediated apoptosis of lymphocytes and hepatocytes. Cell Death Differ 2009;16:1062-70.